Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Exploratory Study to Evaluate Biomarkers in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Patients With Unresectable, Advanced and Recurrent Non-small Cell Lung Cancer or Extensive Disease Small Cell Lung Cancer (J-TAIL-2)

NCT04818983 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT04818983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04818983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Exploratory Study to Evaluate Biomarkers in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Patients With Unresectable, Advanced and Recurrent Non-small Cell Lung Cancer or Extensive Disease Small Cell Lung Cancer (J-TAIL-2)
Lead sponsor
Chugai Pharmaceutical
Phase
Observational
Overall status
Completed
Start date
April 7, 2021
Completion date
February 3, 2023
Enrollment
470 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

extensive disease small cell lung cancer, non-small cell lung cancer